Home › Companies › Iovance Biotherapeutics, Inc. › 2025-2026

Iovance Biotherapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Iovance Biotherapeutics, Inc.’s Form 8-K, filed 2026-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

15Reported items
233Asset managers
2,618Fund votes
2026-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Iovance Biotherapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Iovance Biotherapeutics, Inc.

These tallies are Iovance Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Iovance Biotherapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Dr. Dukes	182,990,471	--	--	16,322,922	130,179,287	Majority: yes
Elect Director: Dr. Countouriotis	186,590,407	--	--	12,722,986	130,179,287	Majority: yes
Elect Director: Mr. Maynard	186,379,215	--	--	12,934,178	130,179,287	Majority: yes
Elect Director: Mr. Rothbaum	183,881,242	--	--	15,432,151	130,179,287	Majority: yes
Elect Director: Dr. Vogt	181,341,958	--	--	17,971,435	130,179,287	Majority: yes
Elect Director: Dr. Weiser	185,454,684	--	--	13,858,709	130,179,287	Majority: yes

This meeting is also recorded here as 2026-06-04; both records come from the same filing, so the date should be checked against it.

Source: Iovance Biotherapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-10 — read the filing on EDGAR.

How asset managers voted at the Iovance Biotherapeutics, Inc. 2025-2026 meeting

Each item below shows how the 233 asset managers that disclosed a Iovance Biotherapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Iovance Biotherapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, by non-binding advisory vote, the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

84% fund support · no official result

FOR 83%AGAINST 16%

The 224 asset managers below cast 84% of the shares they voted on this item FOR (107,297,610 for, 20,167,765 against).

FOR: 107,297,610 (83.5%)AGAINST: 20,167,765 (15.7%)ABSTAIN: 1,056,439 (0.8%)NOT VOTED: 4,791 (0.0%)

Largest asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers;” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
MHR FUND MANAGEMENT LLC	29,053,951	0	0	For
Vanguard	27,568,731	15,366	12	For
BlackRock	9,988,533	41,714	0	For
Invenomic Capital Management LP	7,849,453	0	0	For
Charles Schwab	5,574,293	0	0	For
State Street	4,429,454	59,112	0	For
T. Rowe Price	0	3,990,764	0	Against
Nuveen	3,586,952	0	0	For
TIAA	3,555,426	0	0	For
MARSHALL WACE, LLP	2,244,074	0	0	For
Northern Trust	1,924,938	88,803	0	For
DE Shaw	0	1,901,240	0	Against
Two Sigma	0	1,861,218	0	Against
Knott David M Jr	0	1,600,000	0	Against
Fidelity	1,475,543	0	0	For
WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC	1,369,410	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,295,841	0	0	For
C WorldWide Asset Management Fondsmaeglerselskab A/S	0	1,260,000	0	Against
RICE HALL JAMES & ASSOCIATES, LLC	1,171,840	0	0	For
Mirador Capital Partners LP	0	0	1,054,098	Abstain
American Century	0	759,447	0	Against
Equitable	482,869	245,331	0	For
JPMorgan	719,138	0	0	For
Goldman Sachs	714,438	0	0	For
STIFEL NICOLAUS & CO INC \MO\	0	712,904	0	Against

Showing the 25 largest of 224 asset managers. See all 224 in the interactive database.

2. To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

21% fund support · no official result

ONE YEAR 74%1 YEAR 23%

The 188 asset managers below cast 21% of the shares they voted on this item FOR (45,470 for, 171,366 against).

FOR: 45,470 (0.1%)AGAINST: 171,366 (0.2%)ABSTAIN: 2,348 (0.0%)ONE YEAR: 62,110,073 (73.6%)1 YEAR: 19,808,083 (23.5%)3 YEARS: 1,172,447 (1.4%)THREE YEARS: 616,556 (0.7%)ANNUAL: 473,389 (0.6%)1-YEAR: 8,539 (0.0%)1.0: 721 (0.0%)2.0: 15 (0.0%)3.0: 11 (0.0%)

Largest asset managers voting on “To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named e” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	Abstain	Vote
Vanguard	19	One Year
BlackRock	0	1 Year
Palo Alto Investors LP	0	1 Year
State Street	0	One Year
T. Rowe Price	0	One Year
Nuveen	0	One Year
TIAA	0	One Year
Northern Trust	0	1 Year
DE Shaw	0	One Year
Two Sigma	0	One Year
Knott David M Jr	0	One Year
Fidelity	0	One Year
WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Mirador Capital Partners LP	0	3 Years
American Century	0	One Year
Equitable	0	One Year
JPMorgan	0	One Year
Goldman Sachs	0	One Year
STIFEL NICOLAUS & CO INC \MO\	0	One Year
WELLS FARGO CLEARING SERVICES, LLC	0	1 Year
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	0	One Year
RBC Capital Markets, LLC	0	One Year
Dimensional	0	Three Years
AQR	0	One Year

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

3. To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,000,000 shares;

COMPENSATION

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 54 asset managers below cast 99.9% of the shares they voted on this item FOR (44,920,167 for, 84 against).

FOR: 44,920,167 (100.0%)AGAINST: 84 (0.0%)ABSTAIN: 8 (0.0%)

Largest asset managers voting on “To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Compa” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	24,929,144	84	8	For
BlackRock	4,087,830	0	0	For
TIAA	3,555,426	0	0	For
Charles Schwab	2,786,433	0	0	For
T. Rowe Price	1,533,294	0	0	For
Fidelity	1,422,243	0	0	For
State Street	1,196,441	0	0	For
Equitable	728,200	0	0	For
JPMorgan	719,138	0	0	For
Northern Trust	536,284	0	0	For
ETFis Series Trust I	413,436	0	0	For
American Century	379,377	0	0	For
AIG/SunAmerica	281,698	0	0	For
Tema ETF Trust	278,236	0	0	For
ProShares	256,123	0	0	For
Lincoln Financial	245,615	0	0	For
Global X	158,457	0	0	For
Bridge Builder Trust	150,706	0	0	For
John Hancock	146,797	0	0	For
SEI	132,390	0	0	For
Dimensional	111,269	0	0	For
Direxion Shares ETF Trust	110,628	0	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	0	For
Blackstone Alternative Investment Funds	82,893	0	0	For
Jackson National	75,670	0	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026;

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 53 asset managers below cast 99.9% of the shares they voted on this item FOR (44,911,701 for, 7 against).

FOR: 44,911,701 (100.0%)AGAINST: 7 (0.0%)ABSTAIN: 10 (0.0%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	24,929,217	7	10	For
BlackRock	4,087,830	0	0	For
TIAA	3,555,426	0	0	For
Charles Schwab	2,786,433	0	0	For
T. Rowe Price	1,533,294	0	0	For
Fidelity	1,422,243	0	0	For
State Street	1,196,441	0	0	For
Equitable	728,200	0	0	For
JPMorgan	719,138	0	0	For
Northern Trust	536,284	0	0	For
ETFis Series Trust I	413,436	0	0	For
American Century	379,377	0	0	For
AIG/SunAmerica	281,698	0	0	For
Tema ETF Trust	278,236	0	0	For
ProShares	256,123	0	0	For
Lincoln Financial	245,615	0	0	For
Global X	158,457	0	0	For
Bridge Builder Trust	150,706	0	0	For
John Hancock	146,797	0	0	For
SEI	132,390	0	0	For
Dimensional	111,269	0	0	For
Direxion Shares ETF Trust	110,628	0	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	0	For
Blackstone Alternative Investment Funds	82,893	0	0	For
Jackson National	75,670	0	0	For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

5. To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 500,000,000 shares to 650,000,000 shares; and

CAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 53 asset managers below cast 99.9% of the shares they voted on this item FOR (44,911,591 for, 119 against).

FOR: 44,911,591 (100.0%)AGAINST: 119 (0.0%)ABSTAIN: 8 (0.0%)

Largest asset managers voting on “To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized ” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	24,929,107	119	8	For
BlackRock	4,087,830	0	0	For
TIAA	3,555,426	0	0	For
Charles Schwab	2,786,433	0	0	For
T. Rowe Price	1,533,294	0	0	For
Fidelity	1,422,243	0	0	For
State Street	1,196,441	0	0	For
Equitable	728,200	0	0	For
JPMorgan	719,138	0	0	For
Northern Trust	536,284	0	0	For
ETFis Series Trust I	413,436	0	0	For
American Century	379,377	0	0	For
AIG/SunAmerica	281,698	0	0	For
Tema ETF Trust	278,236	0	0	For
ProShares	256,123	0	0	For
Lincoln Financial	245,615	0	0	For
Global X	158,457	0	0	For
Bridge Builder Trust	150,706	0	0	For
John Hancock	146,797	0	0	For
SEI	132,390	0	0	For
Dimensional	111,269	0	0	For
Direxion Shares ETF Trust	110,628	0	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	0	For
Blackstone Alternative Investment Funds	82,893	0	0	For
Jackson National	75,670	0	0	For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

6. To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6.

OTHER

93% fund support · no official result

FOR 93%

The 53 asset managers below cast 93% of the shares they voted on this item FOR (41,865,879 for, 3,045,828 against).

FOR: 41,865,879 (93.2%)AGAINST: 3,045,828 (6.8%)ABSTAIN: 10 (0.0%)

Largest asset managers voting on “To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not ” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	24,929,101	122	10	For
BlackRock	4,087,830	0	0	For
TIAA	3,555,426	0	0	For
Charles Schwab	2,786,433	0	0	For
T. Rowe Price	0	1,533,294	0	Against
Fidelity	1,422,243	0	0	For
State Street	3,744	1,192,697	0	Against
Equitable	687,509	40,691	0	For
JPMorgan	719,138	0	0	For
Northern Trust	536,284	0	0	For
ETFis Series Trust I	413,436	0	0	For
American Century	379,377	0	0	For
AIG/SunAmerica	281,698	0	0	For
Tema ETF Trust	278,236	0	0	For
ProShares	256,123	0	0	For
Lincoln Financial	41,415	204,200	0	Against
Global X	158,457	0	0	For
Bridge Builder Trust	150,706	0	0	For
John Hancock	87,510	59,287	0	For
SEI	132,390	0	0	For
Dimensional	111,269	0	0	For
Direxion Shares ETF Trust	110,628	0	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	0	For
Blackstone Alternative Investment Funds	82,893	0	0	For
Jackson National	75,670	0	0	For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

7. To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 186,590,407WITHHELD: 12,722,986

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Countouriotis”): 186,590,407 for, 12,722,986 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 438,106,537 outstanding shares: 43% for, 3% withheld (45.5% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (44,849,894 for, 0 against).

FOR 99.8%

FOR: 44,849,894 (99.9%)ABSTAIN: 61,794 (0.1%)

Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	24,898,448	30,787	For
BlackRock	4,087,830	0	For
TIAA	3,555,426	0	For
Charles Schwab	2,786,433	0	For
T. Rowe Price	1,533,294	0	For
Fidelity	1,422,243	0	For
State Street	1,195,138	1,303	For
Equitable	728,200	0	For
JPMorgan	719,138	0	For
Northern Trust	536,284	0	For
ETFis Series Trust I	413,436	0	For
American Century	379,377	0	For
AIG/SunAmerica	281,698	0	For
Tema ETF Trust	278,236	0	For
ProShares	256,123	0	For
Lincoln Financial	245,615	0	For
Global X	158,457	0	For
Bridge Builder Trust	150,706	0	For
John Hancock	146,797	0	For
SEI	132,390	0	For
Dimensional	111,269	0	For
Direxion Shares ETF Trust	110,628	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	For
Blackstone Alternative Investment Funds	82,893	0	For
Jackson National	75,670	0	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

8. To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 181,341,958WITHHELD: 17,971,435

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Vogt”): 181,341,958 for, 17,971,435 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 438,106,537 outstanding shares: 41% for, 4% withheld (45.5% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (44,911,608 for, 0 against).

FOR 99.9%

FOR: 44,911,608 (100.0%)ABSTAIN: 79 (0.0%)

Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	24,929,156	79	For
BlackRock	4,087,830	0	For
TIAA	3,555,426	0	For
Charles Schwab	2,786,433	0	For
T. Rowe Price	1,533,294	0	For
Fidelity	1,422,243	0	For
State Street	1,196,441	0	For
Equitable	728,200	0	For
JPMorgan	719,138	0	For
Northern Trust	536,284	0	For
ETFis Series Trust I	413,436	0	For
American Century	379,377	0	For
AIG/SunAmerica	281,698	0	For
Tema ETF Trust	278,236	0	For
ProShares	256,123	0	For
Lincoln Financial	245,615	0	For
Global X	158,457	0	For
Bridge Builder Trust	150,706	0	For
John Hancock	146,797	0	For
SEI	132,390	0	For
Dimensional	111,269	0	For
Direxion Shares ETF Trust	110,628	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	For
Blackstone Alternative Investment Funds	82,893	0	For
Jackson National	75,670	0	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

9. To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Iain Dukes, D. Phil.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 182,990,471WITHHELD: 16,322,922

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Dukes”): 182,990,471 for, 16,322,922 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 438,106,537 outstanding shares: 42% for, 4% withheld (45.5% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (44,298,375 for, 0 against).

FOR 99%

FOR: 44,298,375 (98.6%)ABSTAIN: 613,313 (1.4%)

Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	24,883,550	45,685	For
BlackRock	4,087,830	0	For
TIAA	3,555,426	0	For
Charles Schwab	2,786,433	0	For
T. Rowe Price	1,533,294	0	For
Fidelity	1,422,243	0	For
State Street	1,195,138	1,303	For
Equitable	728,200	0	For
JPMorgan	719,138	0	For
Northern Trust	0	536,284	Abstain
ETFis Series Trust I	413,436	0	For
American Century	379,377	0	For
AIG/SunAmerica	281,698	0	For
Tema ETF Trust	278,236	0	For
ProShares	256,123	0	For
Lincoln Financial	245,615	0	For
Global X	158,457	0	For
Bridge Builder Trust	150,706	0	For
John Hancock	146,797	0	For
SEI	132,390	0	For
Dimensional	111,269	0	For
Direxion Shares ETF Trust	110,628	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	For
Blackstone Alternative Investment Funds	82,893	0	For
Jackson National	75,670	0	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

10. To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 185,454,684WITHHELD: 13,858,709

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Weiser”): 185,454,684 for, 13,858,709 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 438,106,537 outstanding shares: 42% for, 3% withheld (45.5% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (44,645,251 for, 0 against).

FOR 99.4%

FOR: 44,645,251 (99.4%)ABSTAIN: 266,437 (0.6%)

Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	24,898,445	30,790	For
BlackRock	4,087,830	0	For
TIAA	3,555,426	0	For
Charles Schwab	2,786,433	0	For
T. Rowe Price	1,533,294	0	For
Fidelity	1,422,243	0	For
State Street	1,195,138	1,303	For
Equitable	523,560	204,640	For
JPMorgan	719,138	0	For
Northern Trust	536,284	0	For
ETFis Series Trust I	413,436	0	For
American Century	379,377	0	For
AIG/SunAmerica	281,698	0	For
Tema ETF Trust	278,236	0	For
ProShares	256,123	0	For
Lincoln Financial	245,615	0	For
Global X	158,457	0	For
Bridge Builder Trust	150,706	0	For
John Hancock	146,797	0	For
SEI	132,390	0	For
Dimensional	111,269	0	For
Direxion Shares ETF Trust	110,628	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	For
Blackstone Alternative Investment Funds	82,893	0	For
Jackson National	75,670	0	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

11. To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Ryan Maynard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 186,379,215WITHHELD: 12,934,178

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Maynard”): 186,379,215 for, 12,934,178 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 438,106,537 outstanding shares: 43% for, 3% withheld (45.5% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (44,862,682 for, 0 against).

FOR 99.8%

FOR: 44,862,682 (99.9%)ABSTAIN: 49,005 (0.1%)

Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	24,883,556	45,679	For
BlackRock	4,087,830	0	For
TIAA	3,555,426	0	For
Charles Schwab	2,786,433	0	For
T. Rowe Price	1,533,294	0	For
Fidelity	1,422,243	0	For
State Street	1,195,100	1,341	For
Equitable	728,200	0	For
JPMorgan	719,138	0	For
Northern Trust	536,284	0	For
ETFis Series Trust I	413,436	0	For
American Century	379,377	0	For
AIG/SunAmerica	281,698	0	For
Tema ETF Trust	278,236	0	For
ProShares	256,123	0	For
Lincoln Financial	245,615	0	For
Global X	158,457	0	For
Bridge Builder Trust	150,706	0	For
John Hancock	146,797	0	For
SEI	132,390	0	For
Dimensional	111,269	0	For
Direxion Shares ETF Trust	110,628	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	For
Blackstone Alternative Investment Funds	82,893	0	For
Jackson National	75,670	0	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

12. To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Wayne P. Rothbaum

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 183,881,242WITHHELD: 15,432,151

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Rothbaum”): 183,881,242 for, 15,432,151 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 438,106,537 outstanding shares: 42% for, 4% withheld (45.5% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (44,877,604 for, 0 against).

FOR 99.9%

FOR: 44,877,604 (99.9%)ABSTAIN: 34,084 (0.1%)

Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	24,898,439	30,796	For
BlackRock	4,087,830	0	For
TIAA	3,555,426	0	For
Charles Schwab	2,786,433	0	For
T. Rowe Price	1,533,294	0	For
Fidelity	1,422,243	0	For
State Street	1,195,138	1,303	For
Equitable	728,200	0	For
JPMorgan	719,138	0	For
Northern Trust	536,284	0	For
ETFis Series Trust I	413,436	0	For
American Century	379,377	0	For
AIG/SunAmerica	281,698	0	For
Tema ETF Trust	278,236	0	For
ProShares	256,123	0	For
Lincoln Financial	245,615	0	For
Global X	158,457	0	For
Bridge Builder Trust	150,706	0	For
John Hancock	146,797	0	For
SEI	132,390	0	For
Dimensional	111,269	0	For
Direxion Shares ETF Trust	110,628	0	For
CLEARWATER INVESTMENT TRUST	99,089	0	For
Blackstone Alternative Investment Funds	82,893	0	For
Jackson National	75,670	0	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

13. To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

— fund support · no official result

1 YEAR 99.7%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 19,888,235 (99.7%)ONE YEAR: 50,414 (0.3%)NOT VOTED: 4,791 (0.0%)

Largest asset managers voting on “To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named execu” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Invenomic Capital Management LP	0	0	0	0	1 Year
Charles Schwab	0	0	0	0	1 Year
MARSHALL WACE, LLP	0	0	0	0	1 Year
C WorldWide Asset Management Fondsmaeglerselskab A/S	0	0	0	0	1 Year
RICE HALL JAMES & ASSOCIATES, LLC	0	0	0	0	1 Year
Raiffeisen Bank International AG	0	0	0	0	1 Year
SEI	0	0	0	0	1 Year
WASHINGTON STATE INVESTMENT BOARD	0	0	0	0	1 Year
Global X	0	0	0	0	1 Year
Russell Investments	0	0	0	0	1 Year
CLEARWATER INVESTMENT TRUST	0	0	0	0	1 Year
BANK OF AMERICA NA	0	0	0	0	1 Year
Arizona State Retirement System	0	0	0	0	1 Year
LOS ANGELES CAPITAL MANAGEMENT LLC	0	0	0	0	1 Year
GRANDFIELD & DODD, LLC	0	0	0	0	1 Year
Neuberger Berman	0	0	0	0	1 Year
Prudential/PGIM	0	0	0	0	1 Year
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	0	0	0	0	1 Year
Vanguard	0	0	0	0	One Year
Venerable Variable Insurance Trust	0	0	0	0	1 Year
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	0	0	0	0	1 Year
Wealthfront Advisers LLC	0	0	0	0	1 Year
BALYASNY ASSET MANAGEMENT L.P.	0	0	0	0	1 Year
Nationwide	0	0	0	0	One Year
NEW YORK STATE COMMON RETIREMENT FUND	0	0	0	0	1 Year

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

14. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

0.2% fund support · no official result

AGAINST 99.8%

The 4 asset managers below cast 0.2% of the shares they voted on this item FOR (1,121 for, 709,674 against).

FOR: 1,121 (0.2%)AGAINST: 709,674 (99.8%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
SECTOR GAMMA AS	0	709,674	Against
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	700	0	For
Coyle Financial Counsel LLC	421	0	For
Torrey Growth & Income Advisors	0	0	--

15. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTESCOMPENSATION

100% fund support · no official result

FOR 99.9%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (709,674 for, 0 against).

FOR: 709,674 (99.9%)1 YEAR: 421 (0.1%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Iovance Biotherapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
SECTOR GAMMA AS	709,674	0	0	0	For
Coyle Financial Counsel LLC	0	0	0	0	1 Year

Largest Iovance Biotherapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Iovance Biotherapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 438,106,537 shares outstanding at the time of that meeting.

Top Iovance Biotherapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	MHR FUND MANAGEMENT LLC	6.63%
2	Vanguard	6.30%
3	BlackRock	2.29%
4	Invenomic Capital Management LP	1.79%
5	Charles Schwab	1.27%
6	State Street	1.02%
7	T. Rowe Price	0.91%
8	Nuveen	0.82%
9	TIAA	0.81%
10	MARSHALL WACE, LLP	0.51%

Reported Iovance Biotherapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Iovance Biotherapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock, Inc.	7.62%	13G
New York, NY	6.85%	DEF14A
Wayne Rothbaum	6.85%	DEF14A
Malvern, PA	5.72%	DEF14A
STATE STREET CORPORATION	5.59%	13G
Frederick G. Vogt, Ph.D., J.D.	0.46%	DEF14A
Raj K. Puri, M.D., Ph.D.	0.15%	DEF14A
Iain Dukes, D. Phil.	0.14%	DEF14A
Igor Bilinsky, Ph.D.	0.10%	DEF14A
Michael Weiser, M.D., Ph.D.	0.07%	DEF14A

Percentages above are of 438,106,537 shares outstanding, as reported by Iovance Biotherapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Iovance Biotherapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Iovance Biotherapeutics, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 233 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,618 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Iovance Biotherapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the compensation of our named executive officers; — the reporting funds cast 84% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Iovance Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).